Aurum Biosciences Ltd is a clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, oncology, inflammatory conditions, spinal cord injury, and dementia. Preclinical development has been completed in the lead indication (AIS) and approval has been granted to initiate clinical studies in acute stroke patients. Concurrently, Aurum is pursuing opportunities to develop its pipeline indications with a focus on inflammatory conditions and oncology.